This tumor antigen-loaded nanoerythrosomes elicited antigen responses in vivo, and when nanoerythrosomes combined with anti-programmed death ligand 1 (PD-L1), it can inhibit tumor growth in B16F10 and 4T1 tumor models. This evidence concerns the gene CD274 and neoplasm.